Transforming Oncology Together — CancerX Startups Demonstrate the Power of AI at Moffitt Panel

CancerX took center stage at Moffitt Cancer Center's Business of Biotech conference showcasing the remarkable progress of startups in its accelerator program. The highlight was an insightful panel titled "AI and Digital Health: Transforming the Future of Oncology" featuring both alumni and current participants of the CancerX accelerator. The panel, moderated by Kamal Jethwani, CancerX lead, brought together four innovative companies that represent the cutting edge of AI-powered cancer care solutions. "Our greatest challenge isn't creating breakthrough innovations—it's ensuring those innovations reach every patient who needs them, regardless of geography, socioeconomic status, or health literacy," Dr. Jethwani emphasized during the discussion.

The future of cancer innovation was well-represented by two successful CancerX accelerator alumni: Bea Bakshi, CEO and Co-founder of C the Signs, and Aaron Brauser, CEO and Co-founder of Realyze Intelligence. Their participation highlighted how the accelerator program has already produced companies making significant strides in improving cancer care through technology. Alongside these alumni, two promising current cohort participants demonstrated the ongoing impact of the CancerX program: Eirini Schlosser, CEO and Co-founder of Dyania Health, and Aabid Shariff, CEO and Co-founder of Citrus Oncology. Together, these leaders exemplified the continuum of innovation flowing through the accelerator.

In the fight against cancer, collaboration isn't just beneficial—it's essential.

This sentiment was evident throughout the panel as participants discussed how the CancerX accelerator has helped them navigate the complex healthcare landscape and forge critical connections with clinical partners, investors, and industry leaders. The panelists shared their experiences in leveraging AI and digital technologies to address critical gaps in cancer care. From early detection and risk stratification to improving clinical workflows and patient engagement, each company presented unique approaches to solving persistent challenges in oncology.

The most promising cancer therapies can only transform lives if they successfully navigate the journey from lab bench to bedside. Throughout the discussion, the CEOs highlighted how CancerX has provided them with strategic guidance on overcoming commercial and regulatory hurdles that often slow this critical transition. The accelerator's support has proven invaluable in helping these companies scale their innovations and reach more patients more quickly. Attendees were captivated by the real-world impact these companies are already having in clinical settings. Innovation in cancer care requires both scientific brilliance and business acumen—a combination that the CancerX accelerator actively cultivates in its participants.

The CancerX accelerator serves as a powerful connector within the cancer innovation ecosystem, compressing the traditionally lengthy timeline between discovery and implementation. By providing structured support to promising startups, CancerX is delivering on its mission to accelerate better outcomes for cancer patients through technological innovation. The enthusiastic reception to the panel reflected the growing recognition of AI and digital health as transformative forces in oncology. As these technologies continue to mature, the companies supported by the CancerX accelerator are positioned to lead the next wave of cancer care innovation.

The future of cancer care will be written by those who can move seamlessly between breakthrough science and practical implementation.

The panelists exemplified this ability, demonstrating how the CancerX accelerator has equipped them with both the technical insights and business strategies needed for success in the complex healthcare marketplace. For those inspired to contribute to this vital mission, the CancerX initiative offers structured pathways to participate in transforming cancer care through collaborative innovation.

For more information and to join the CancerX community on the Constellation platform become a member today.